Lumasiran sodiumProduct ingredient for Lumasiran
- Name
- Lumasiran sodium
- Drug Entry
- Lumasiran
Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1).6 This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation.6 These patients experience frequent kidney stones, nephrocalcinosis, and renal failure.6
Oxlumo, producted by Alnylam Pharmaceuticals, represents the first approved treatment for PH1.3 Prior to this approval, therapy consisted of symptomatic treatment such as hyperhydration, inhibitors of crystallization, pyridoxine, and renal transplant.6
Lumasiran was granted FDA approval on 23 November 2020.3
- Accession Number
- DBSALT003500
- Structure
- Synonyms
- AD-65585 SODIUM / ALN-65585 SODIUM / ALN-G01 SODIUM / ALN-GO1 SODIUM / OXLUMO / RNA, (GM-SP-AM-SP-CM-UM-UM-UM-(2'-DEOXY-2'-FLUORO)C-AM-(2'-DEOXY-2'-FLUORO)U-(2'-DEOXY-2'-FLUORO)C-(2'-DEOXY-2'-FLUORO)C-UM-GM-GM-AM-AM-AM-UM-AM-UM-AM), 3'-(((2S,4R)-1-(29-((2-(ACETYLAMINO)-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)-14,14-BIS((3-((3-((5-((2-
- UNII
- 67P6XH37HD
- CAS Number
- 1834612-06-4
- External Links
- Wikipedia
- Lumasiran
- Predicted Properties
- Not Available